Trinity Biotech SEC Filings

Type
Report
Date
SCHEDULE 13D/ASCHEDULE 13D/A-Formular1/26/2026
424B3424B3-Formular1/23/2026
EFFECTEFFECT-Formular1/23/2026
F-1F-1-Formular1/15/2026
SCHEDULE 13D/ASCHEDULE 13D/A-Formular12/23/2025
6-K6-K-Formular12/23/2025
6-K6-K-Formular12/23/2025
6-K6-K-Formular12/23/2025
6-K6-K-Formular12/18/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular12/15/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular12/10/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular12/4/2025
6-K6-K-Formular11/21/2025
6-K6-K-Formular11/18/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular10/24/2025
6-K6-K-Formular10/23/2025
6-K6-K-Formular9/30/2025
6-K6-K-Formular9/8/2025
6-K6-K-Formular9/2/2025
6-K6-K-Formular8/20/2025
6-K6-K-Formular8/15/2025
6-K6-K-Formular8/12/2025
6-K6-K-Formular8/8/2025
6-K6-K-Formular7/24/2025
6-K6-K-Formular7/1/2025
6-K6-K-Formular6/24/2025
20-F20-F-Formular5/16/2025
6-K6-K-Formular5/15/2025
NT 20-FNT 20-F-Formular4/30/2025
6-K6-K-Formular4/4/2025
424B3424B3-Formular3/31/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular3/25/2025
F-3F-3-Formular3/21/2025
6-K6-K-Formular3/14/2025
6-K6-K-Formular3/13/2025
6-K6-K-Formular2/28/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular2/14/2025
6-K6-K-Formular2/6/2025
6-K6-K-Formular2/4/2025
6-K6-K-Formular1/29/2025
6-K6-K-Formular1/28/2025
6-K6-K-Formular12/27/2024
424B5424B5-Formular12/27/2024
SCHEDULE 13DSCHEDULE 13D-Formular12/26/2024
6-K6-K-Formular12/26/2024
SCHEDULE 13D/ASCHEDULE 13D/A-Formular12/19/2024
6-K6-K-Formular12/18/2024
6-K6-K-Formular12/17/2024
424B5424B5-Formular12/17/2024
424B3424B3-Formular12/5/2024
EFFECTEFFECT-Formular12/2/2024
F-3/AF-3/A-Formular11/29/2024
F-3F-3-Formular11/15/2024
6-K6-K-Formular11/15/2024
SC 13D/ASC 13D/A-Formular11/14/2024
6-K6-K-Formular11/7/2024
6-K6-K-Formular10/25/2024
6-K6-K-Formular10/25/2024
6-K6-K-Formular10/7/2024
6-K6-K-Formular10/2/2024
6-K6-K-Formular9/30/2024
6-K6-K-Formular9/25/2024
6-K6-K-Formular9/23/2024
424B5424B5-Formular9/20/2024
6-K6-K-Formular9/19/2024
6-K6-K-Formular9/10/2024
6-K6-K-Formular9/5/2024
6-K6-K-Formular9/5/2024
6-K6-K-Formular9/4/2024
6-K6-K-Formular8/29/2024
424B5424B5-Formular8/28/2024
6-K6-K-Formular8/27/2024
6-K6-K-Formular8/21/2024
6-K6-K-Formular8/20/2024
6-K6-K-Formular8/7/2024
6-K6-K-Formular8/7/2024
6-K6-K-Formular7/12/2024
20-F/A20-F/A-Formular7/12/2024
424B5424B5-Formular7/12/2024
6-K6-K-Formular7/11/2024
EFFECTEFFECT-Formular6/28/2024
F-3/AF-3/A-Formular6/28/2024
F-3F-3-Formular6/21/2024
6-K6-K-Formular5/28/2024
6-K6-K-Formular5/16/2024
EFFECTEFFECT-Formular5/7/2024
424B3424B3-Formular5/7/2024
CORRESPCORRESP-Formular5/3/2024
UPLOADUPLOAD-Formular5/2/2024
SC 13D/ASC 13D/A-Formular5/1/2024
F-3F-3-Formular4/30/2024
20-F20-F-Formular4/30/2024
6-K6-K-Formular4/30/2024
6-K6-K-Formular4/5/2024
6-K6-K-Formular2/20/2024
6-K6-K-Formular2/20/2024
424B3424B3-Formular2/15/2024
SC 13DSC 13D-Formular2/9/2024
6-K6-K-Formular2/1/2024
6-K6-K-Formular2/1/2024

Trinity Biotech Documents 2026

This page contains all official documents and SEC filings for Trinity Biotech stock (TRIB, ISIN: US8964385046). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Trinity Biotech's regulatory filings.

Trinity Biotech Stock analysis

Trinity Biotech Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland.